Tim Wright, Editor, Contract Pharma01.27.21
In response to heightened customer demand, Grand River Aseptic Manufacturing (GRAM), a parenteral contract development and manufacturing organization (CDMO), has purchased an additional Bausch+Ströbel vial filler with SKAN Isolator and a new VarioSys syringe and vial filler. The new equipment will significantly increase GRAM's future capacity.
The Bausch+Ströbel filler with SKAN isolator is tailored to meet the critical needs of GRAM's growing customer base and is a duplicate of GRAM's current vial filler that reached GMP production in September 2020. The duplication will allow experienced experts to qualify the equipment and reach production swiftly. Through its interchangeable design, the VarioSys system provides the flexibility to increase production capacity with the option to dedicate complete modules to individual drug products. Equipment is scheduled for delivery during the first quarter of 2022.
New equipment will significantly increase GRAM's future capacity
"We are excited that GRAM's commitment to exceptional results has led to the need to continue to increase our capacity so soon after we completed our large-scale facility expansion," said Tom Ross, president and chief executive officer, GRAM. "This new equipment will afford GRAM the flexibility and capacity to continue delivering for our customers using world class equipment that is supported by talented, agile team members."
Andre Zdunczyk, regional business development director for USA at Bausch+Ströbel, said, "The pharmaceutical manufacturing industry is being challenged—now more than ever—to be more cost effective and to reduce timelines for life-saving drugs. CDMOs, like GRAM, that are well-equipped to operate in a fast-paced environment without sacrificing quality are great partners for improving time to market."
While GRAM continues to invest in sophisticated technology, the CDMO is also dedicating more resources to its expanding team. GRAM added nearly 100 new employees in 2020 and will continue to grow to serve new client demand and as equipment and facilities expand.
The Bausch+Ströbel filler with SKAN isolator is tailored to meet the critical needs of GRAM's growing customer base and is a duplicate of GRAM's current vial filler that reached GMP production in September 2020. The duplication will allow experienced experts to qualify the equipment and reach production swiftly. Through its interchangeable design, the VarioSys system provides the flexibility to increase production capacity with the option to dedicate complete modules to individual drug products. Equipment is scheduled for delivery during the first quarter of 2022.
New equipment will significantly increase GRAM's future capacity
"We are excited that GRAM's commitment to exceptional results has led to the need to continue to increase our capacity so soon after we completed our large-scale facility expansion," said Tom Ross, president and chief executive officer, GRAM. "This new equipment will afford GRAM the flexibility and capacity to continue delivering for our customers using world class equipment that is supported by talented, agile team members."
Andre Zdunczyk, regional business development director for USA at Bausch+Ströbel, said, "The pharmaceutical manufacturing industry is being challenged—now more than ever—to be more cost effective and to reduce timelines for life-saving drugs. CDMOs, like GRAM, that are well-equipped to operate in a fast-paced environment without sacrificing quality are great partners for improving time to market."
While GRAM continues to invest in sophisticated technology, the CDMO is also dedicating more resources to its expanding team. GRAM added nearly 100 new employees in 2020 and will continue to grow to serve new client demand and as equipment and facilities expand.
